



Blincyto® (blinatumomab) (Intravenous)

Document Number: IC-0225

Last Review Date: 03/01/2022

Date of Origin: 12/16/2014

Dates Reviewed: 12/2014, 09/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 04/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 03/2021, 03/2022

I. Length of Authorization ¹

- Acute Lymphoblastic Leukemia (ALL) – Relapsed or refractory disease:
 - Initial coverage will be provided for 30 weeks for a total of five cycles (2 cycles of induction followed by 3 cycles of consolidation)
 - Continued coverage will be provided every 24 weeks for a maximum of two additional authorizations (4 cycles of continued therapy)
- Acute Lymphoblastic Leukemia (ALL) – MRD+, persistent/rising MRD, or less than complete response to induction therapy:
 - Initial coverage will be provided for 24 weeks for a total of four cycles (1 cycle of induction followed by 3 cycles of consolidation)
 - Continued coverage may not be renewed

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Blincyto 35 mcg powder for injection: 28 vials per 42 day supply

B. Max Units (per dose and over time) [HCPCS Unit]:

- Acute Lymphoblastic Leukemia (ALL) (Adult/Pediatric)
 - Cycle 1 – 5 (Induction/Consolidation)
 - 980 billable units per 42 days
 - Cycle 6 – 9 (Continued Therapy)
 - 980 billable units per 84 days

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

Universal Criteria ¹

- Patient has not received a live vaccine within 2 weeks prior to initiating therapy and will not receive concurrent treatment with live vaccine while on therapy; **AND**

Acute Lymphoblastic Leukemia (ALL) – Adult* † ‡ ◊ ¹⁻⁸

- Patient is at least 15 years of age; **AND**
- Patient has B-cell precursor ALL; **AND**
 - Patient has persistent/rising minimal residual disease (MRD); **AND**
 - Used following a complete response to induction therapy; **AND**
 - Used with or without a tyrosine kinase inhibitor (TKI [e.g., bosutinib, dasatinib, imatinib, nilotinib, or ponatinib]) for Philadelphia chromosome-positive (Ph+) disease; **OR**
 - Patient has minimal residual disease positive (MRD+) ALL; **AND**
 - Used following a complete response/remission to induction therapy; **AND**
 - Used as a single agent; **OR**
 - Patient has relapsed or refractory disease; **AND**
 - Used with or without a TKI (e.g., bosutinib, dasatinib, imatinib, nilotinib, or ponatinib) for Ph+ disease; **OR**
 - Used as a single agent for Philadelphia chromosome-negative (Ph-) disease

**NCCN recommendations for ALL may be applicable to adolescent and young adult (AYA) patients within the age range of 15-39 years.*

Pediatric Acute Lymphoblastic Leukemia (ALL) † ‡ ◊ ¹⁻⁸

- Patient is at least 1 month of age; **AND**
- Patient has B-cell precursor ALL; **AND**
- Used as a single agent; **AND**
 - Patient has minimal residual disease positive (MRD+) ALL; **AND**
 - Patient is in first or second complete remission; **OR**
 - Used after or at the end of consolidation therapy; **OR**
 - Used for less than complete response to induction therapy; **AND**
 - Patient has Philadelphia chromosome-positive (Ph+) disease; **OR**
 - Patient has relapsed or refractory disease

**NCCN recommendations for Pediatric ALL may be applicable to certain adolescent and young adult (AYA) patients up to 30 years of age.*

† FDA Approved Indication(s); ‡ Compendium Recommended Indication(s); ◊ Orphan Drug

IV. Renewal Criteria ^{1,2}

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: Cytokine Release Syndrome (CRS), neurological toxicities, serious infections, pancreatitis, tumor lysis syndrome (TLS), neutropenia/febrile neutropenia, elevated liver enzymes, leukoencephalopathy, etc.; **AND**
- Treatment response or stabilization of disease as indicated by CBC, bone marrow cytogenic analysis, QPCR, or FISH; **AND**

Acute Lymphoblastic Leukemia (Adult/Pediatric) – Relapsed or refractory disease

- Patient has not exceeded 4 cycles of continued therapy or 9 total cycles of therapy for the treatment of relapsed or refractory disease

Acute Lymphoblastic Leukemia (Adult/Pediatric) – MRD+, persistent/rising MRD, or less than complete response to induction therapy

- Continued coverage may not be renewed

V. Dosage/Administration ¹

Indication	Dose
Acute Lymphoblastic Leukemia	<p><u>Relapsed/Refractory Disease*</u></p> <ul style="list-style-type: none"> ➤ Weight greater than or equal to 45 kg <ul style="list-style-type: none"> – <u>Cycle 1 (induction):</u> <ul style="list-style-type: none"> • 9 mcg daily x 7 days, then 28 mcg daily x 21 days in a 42 day cycle – <u>Cycles 2-5 (induction/consolidation):</u> <ul style="list-style-type: none"> • 28 mcg daily x 28 days in a 42 day cycle – <u>Cycles 6-9 (continued therapy):</u> <ul style="list-style-type: none"> • 28 mcg daily x 28 days in an 84 day cycle ➤ Weight less than 45 kg <ul style="list-style-type: none"> – <u>Cycle 1 (induction) :</u> <ul style="list-style-type: none"> • 5 mcg/m²/day (not to exceed 9 mcg/day) x 7 days, then 15 mcg/m²/day (not to exceed 28 mcg/day) x 21 days in a 42 day cycle – <u>Cycles 2-5 (induction/consolidation):</u> <ul style="list-style-type: none"> • 15 mcg/m²/day (not to exceed 28 mcg/day) x 28 days in a 42 day cycle – <u>Cycles 6-9 (continued therapy):</u> <ul style="list-style-type: none"> • 15 mcg/m²/day (not to exceed 28 mcg/day) x 28 days in an 84 day cycle <p><i>*Up to 9 total cycles of therapy.</i></p>
	<p><u>MRD+ or Persistent/Rising MRD or Less than Complete Response to Induction Therapy*</u></p> <ul style="list-style-type: none"> ➤ Weight greater than or equal to 45 kg

	<ul style="list-style-type: none"> - <u>Cycle 1 (induction):</u> <ul style="list-style-type: none"> • 28 mcg daily x 28 days in a 42-day cycle - <u>Cycles 2-4 (consolidation):</u> <ul style="list-style-type: none"> • 28 mcg daily x 28 days in a 42 day cycle <p>➤ Weight less than 45 kg</p> <ul style="list-style-type: none"> - <u>Cycle 1 (induction) :</u> <ul style="list-style-type: none"> • 15 mcg/m²/day (not to exceed 28 mcg/day) x 28 days in a 42 day cycle - <u>Cycles 2-4 (consolidation):</u> <ul style="list-style-type: none"> • 15 mcg/m²/day (not to exceed 28 mcg/day) x 28 days in a 42 day cycle <p><i>*Up to 4 total cycles of therapy.</i></p>
--	--

VI. Billing Code/Availability Information

HCPCS Code:

- J9039 – Injection, blinatumomab, 1 microgram; 1 billable unit = 1 microgram

NDC:

- Blincyto 35 mcg single-dose powder for injection: 55513-0160-xx

VII. References

1. Blincyto [package insert]. Thousand Oaks, CA; Amgen, March 2021. Accessed January 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) blinatumomab. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2022.
3. Jen EY, Xu Q, Schetter A, Przepiorka D, et al. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.
4. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
5. Martinelli G, Boissel N, Chevallier P, et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722. J Clin Oncol. 2017 Aug 20;35(24):2856.
6. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Pediatric Acute Lymphoblastic Leukemia 4.2021. National

Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2022.

7. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *Lancet Oncol.* 2015;16(1):57-66.
8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *J Clin Oncol.* 2016;34(36):4381-4389.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.50	Lymphoblastic (diffuse) lymphoma unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma spleen
C83.58	Lymphoblastic (diffuse) lymphoma lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma extranodal and solid organ sites
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC